Showing results (181-190 of 228) with videos related to
Sort By:
Pageof 23
Research Square|November 19, 2025
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective StudyMatthew Hamby, Brian Egleston, Zachary Frosch, et al.Journal of the American Academy of Dermatology|April 8, 2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndromeAmrita Goyal, Daniel O'Leary, Bouthaina Dabaja, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.Pageof 23